BioInvent says Phase 2a BI-1206 plus Keytruda trial in first-line NSCLC, uveal melanoma posts initial data in H2 2026

• BioInvent highlighted new preclinical evidence in JECCR supporting FcγR-blockade combinations to strengthen checkpoint antibody therapies and counter resistance.
• Results have already been published; initial Phase 2a readouts for BI-1206 with pembrolizumab are expected in the second half of 2026.
• BI-1206 supported stronger anti-PD-1 activity by preventing immune-cell loss that can blunt checkpoint therapy in tumors.
• BioInvent also reported BI-1607 improved anti-CTLA-4 activity in models, though the program is paused while resources shift to lead assets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioInvent International AB published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.